Bleeding risk with AZD6140, a reversible P2Y12 receptor antagonist, vs. clopidogrel in patients undergoing coronary artery bypass grafting in the DISPERSE2 trial.
about
Antiplatelet therapy in acute coronary syndromes: focus on ticagrelorTicagrelor: from discovery to Phase III clinical trial.Ischemic and bleeding outcomes after coronary artery bypass grafting among patients initially treated with a P2Y12 receptor antagonist for acute coronary syndromes: Insights on timing of discontinuation of ticagrelor and clopidogrel prior to surgery
P2860
Bleeding risk with AZD6140, a reversible P2Y12 receptor antagonist, vs. clopidogrel in patients undergoing coronary artery bypass grafting in the DISPERSE2 trial.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
Bleeding risk with AZD6140, a ...... afting in the DISPERSE2 trial.
@en
Bleeding risk with AZD6140, a ...... afting in the DISPERSE2 trial.
@nl
type
label
Bleeding risk with AZD6140, a ...... afting in the DISPERSE2 trial.
@en
Bleeding risk with AZD6140, a ...... afting in the DISPERSE2 trial.
@nl
prefLabel
Bleeding risk with AZD6140, a ...... afting in the DISPERSE2 trial.
@en
Bleeding risk with AZD6140, a ...... afting in the DISPERSE2 trial.
@nl
P2093
P1476
Bleeding risk with AZD6140, a ...... afting in the DISPERSE2 trial.
@en
P2093
C P Cannon
P Mitchell
R A Harrington
P304
P356
10.1111/J.1742-1241.2009.02030.X
P577
2009-04-01T00:00:00Z